Toward understanding and exploiting tumor heterogeneity

Ash A. Alizadeh; Victoria Aranda; Alberto Bardelli; Cedric Blanpain; Christoph Bock; Christine Borowski; Carlos Caldas; Andrea Califano; Michael Doherty; Markus Elsner; Manel Esteller; Rebecca Fitzgerald; Jan O. Korbel; Peter Lichter; Christopher E. Mason; Nicholas Navin; Dana Pe'Er; Kornelia Polyak; Charles W.M. Roberts; Lillian Siu; Alexandra Snyder; Hannah Stower; Charles Swanton; Roel G.W. Verhaak; Jean C. Zenklusen; Johannes Zuber; Jessica Zucman-Rossi

doi:10.1038/nm.3915

Toward understanding and exploiting tumor heterogeneity

Ash A. Alizadeh, Victoria Aranda, Alberto Bardelli, Cedric Blanpain, Christoph Bock, Christine Borowski, Carlos Caldas, Andrea Califano, Michael Doherty, Markus Elsner, Manel Esteller, Rebecca Fitzgerald, Jan O. Korbel, Peter Lichter, Christopher E. Mason, Nicholas Navin, Dana Pe'Er, Kornelia Polyak, Charles W.M. Roberts, Lillian SiuAlexandra Snyder, Hannah Stower, Charles Swanton, Roel G.W. Verhaak, Jean C. Zenklusen, Johannes Zuber, Jessica Zucman-Rossi

Bioinformatics & Computational Biology

Research output: Contribution to journal › Review article › peer-review

531 Scopus citations

Abstract

The extent of tumor heterogeneity is an emerging theme that researchers are only beginning to understand. How genetic and epigenetic heterogeneity affects tumor evolution and clinical progression is unknown. The precise nature of the environmental factors that influence this heterogeneity is also yet to be characterized. Nature Medicine, Nature Biotechnology and the Volkswagen Foundation organized a meeting focused on identifying the obstacles that need to be overcome to advance translational research in and tumor heterogeneity. Once these key questions were established, the attendees devised potential solutions. Their ideas are presented here.

Original language	English (US)
Pages (from-to)	846-853
Number of pages	8
Journal	Nature medicine
Volume	21
Issue number	8
DOIs	https://doi.org/10.1038/nm.3915
State	Published - Aug 6 2015

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

MD Anderson CCSG core facilities

Bioinformatics Shared Resource

Access to Document

10.1038/nm.3915

Cite this

Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., Esteller, M., Fitzgerald, R., Korbel, J. O., Lichter, P., Mason, C. E., Navin, N., Pe'Er, D., Polyak, K., Roberts, C. W. M., ... Zucman-Rossi, J. (2015). Toward understanding and exploiting tumor heterogeneity. Nature medicine, 21(8), 846-853. https://doi.org/10.1038/nm.3915

Alizadeh, AA, Aranda, V, Bardelli, A, Blanpain, C, Bock, C, Borowski, C, Caldas, C, Califano, A, Doherty, M, Elsner, M, Esteller, M, Fitzgerald, R, Korbel, JO, Lichter, P, Mason, CE, Navin, N, Pe'Er, D, Polyak, K, Roberts, CWM, Siu, L, Snyder, A, Stower, H, Swanton, C, Verhaak, RGW, Zenklusen, JC, Zuber, J & Zucman-Rossi, J 2015, 'Toward understanding and exploiting tumor heterogeneity', Nature medicine, vol. 21, no. 8, pp. 846-853. https://doi.org/10.1038/nm.3915

@article{fe01f2d13d194ead9fd733acc1cdad9c,

title = "Toward understanding and exploiting tumor heterogeneity",

abstract = "The extent of tumor heterogeneity is an emerging theme that researchers are only beginning to understand. How genetic and epigenetic heterogeneity affects tumor evolution and clinical progression is unknown. The precise nature of the environmental factors that influence this heterogeneity is also yet to be characterized. Nature Medicine, Nature Biotechnology and the Volkswagen Foundation organized a meeting focused on identifying the obstacles that need to be overcome to advance translational research in and tumor heterogeneity. Once these key questions were established, the attendees devised potential solutions. Their ideas are presented here.",

author = "Alizadeh, {Ash A.} and Victoria Aranda and Alberto Bardelli and Cedric Blanpain and Christoph Bock and Christine Borowski and Carlos Caldas and Andrea Califano and Michael Doherty and Markus Elsner and Manel Esteller and Rebecca Fitzgerald and Korbel, {Jan O.} and Peter Lichter and Mason, {Christopher E.} and Nicholas Navin and Dana Pe'Er and Kornelia Polyak and Roberts, {Charles W.M.} and Lillian Siu and Alexandra Snyder and Hannah Stower and Charles Swanton and Verhaak, {Roel G.W.} and Zenklusen, {Jean C.} and Johannes Zuber and Jessica Zucman-Rossi",

year = "2015",

month = aug,

day = "6",

doi = "10.1038/nm.3915",

language = "English (US)",

volume = "21",

pages = "846--853",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Toward understanding and exploiting tumor heterogeneity

AU - Alizadeh, Ash A.

AU - Aranda, Victoria

AU - Bardelli, Alberto

AU - Blanpain, Cedric

AU - Bock, Christoph

AU - Borowski, Christine

AU - Caldas, Carlos

AU - Califano, Andrea

AU - Doherty, Michael

AU - Elsner, Markus

AU - Esteller, Manel

AU - Fitzgerald, Rebecca

AU - Korbel, Jan O.

AU - Lichter, Peter

AU - Mason, Christopher E.

AU - Navin, Nicholas

AU - Pe'Er, Dana

AU - Polyak, Kornelia

AU - Roberts, Charles W.M.

AU - Siu, Lillian

AU - Snyder, Alexandra

AU - Stower, Hannah

AU - Swanton, Charles

AU - Verhaak, Roel G.W.

AU - Zenklusen, Jean C.

AU - Zuber, Johannes

AU - Zucman-Rossi, Jessica

PY - 2015/8/6

Y1 - 2015/8/6

N2 - The extent of tumor heterogeneity is an emerging theme that researchers are only beginning to understand. How genetic and epigenetic heterogeneity affects tumor evolution and clinical progression is unknown. The precise nature of the environmental factors that influence this heterogeneity is also yet to be characterized. Nature Medicine, Nature Biotechnology and the Volkswagen Foundation organized a meeting focused on identifying the obstacles that need to be overcome to advance translational research in and tumor heterogeneity. Once these key questions were established, the attendees devised potential solutions. Their ideas are presented here.

AB - The extent of tumor heterogeneity is an emerging theme that researchers are only beginning to understand. How genetic and epigenetic heterogeneity affects tumor evolution and clinical progression is unknown. The precise nature of the environmental factors that influence this heterogeneity is also yet to be characterized. Nature Medicine, Nature Biotechnology and the Volkswagen Foundation organized a meeting focused on identifying the obstacles that need to be overcome to advance translational research in and tumor heterogeneity. Once these key questions were established, the attendees devised potential solutions. Their ideas are presented here.

UR - http://www.scopus.com/inward/record.url?scp=84938799837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938799837&partnerID=8YFLogxK

U2 - 10.1038/nm.3915

DO - 10.1038/nm.3915

M3 - Review article

C2 - 26248267

AN - SCOPUS:84938799837

SN - 1078-8956

VL - 21

SP - 846

EP - 853

JO - Nature medicine

JF - Nature medicine

IS - 8

ER -

Toward understanding and exploiting tumor heterogeneity

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this